EA202092978A2 - PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION - Google Patents

PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION

Info

Publication number
EA202092978A2
EA202092978A2 EA202092978A EA202092978A EA202092978A2 EA 202092978 A2 EA202092978 A2 EA 202092978A2 EA 202092978 A EA202092978 A EA 202092978A EA 202092978 A EA202092978 A EA 202092978A EA 202092978 A2 EA202092978 A2 EA 202092978A2
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
parenteral
drop injection
relates
obesity
Prior art date
Application number
EA202092978A
Other languages
Russian (ru)
Other versions
EA202092978A3 (en
Inventor
Виктор Александрович Сисев
Original Assignee
Общество с ограниченной ответственностью "Ай Кью Витаминная студия"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество с ограниченной ответственностью "Ай Кью Витаминная студия" filed Critical Общество с ограниченной ответственностью "Ай Кью Витаминная студия"
Publication of EA202092978A2 publication Critical patent/EA202092978A2/en
Publication of EA202092978A3 publication Critical patent/EA202092978A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к области медицины и касается фармацевтической композиции для парентерального капельного введения, предназначенной для лечения ожирения. Четко подобранный, сбалансированный качественный и количественный состав обеспечивает создание лекарственной формы, пригодной для эффективного снижения индекса массы тела в короткие сроки.The invention relates to medicine and relates to a pharmaceutical composition for parenteral drip administration, intended for the treatment of obesity. A well-selected, balanced qualitative and quantitative composition ensures the creation of a dosage form suitable for effective reduction of body mass index in a short time.

EA202092978A 2019-11-11 2020-12-29 PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION EA202092978A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019136114A RU2721605C1 (en) 2019-11-11 2019-11-11 Pharmaceutical composition for parenteral drop introduction

Publications (2)

Publication Number Publication Date
EA202092978A2 true EA202092978A2 (en) 2021-05-31
EA202092978A3 EA202092978A3 (en) 2021-08-31

Family

ID=70803152

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092978A EA202092978A3 (en) 2019-11-11 2020-12-29 PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION

Country Status (2)

Country Link
EA (1) EA202092978A3 (en)
RU (1) RU2721605C1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146234T3 (en) * 1992-10-22 2000-08-01 Yoshitomi Pharmaceutical CONTAINER CONTAINING A TRANSFUSION LIQUID, AND PREPARED TRANSFUSION LIQUID.
RU2426443C2 (en) * 2007-02-23 2011-08-20 Хилл'С Пет Ньютришн, Инк. Compositions and methods for animal weight control (versions)
WO2011119023A1 (en) * 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
WO2014045065A2 (en) * 2012-09-22 2014-03-27 Bslim Holdings Limited Dietary compositions and their uses
EP3379946A1 (en) * 2015-11-27 2018-10-03 DoubleGood AB Food supplement and composition for treating the metabolic syndrome

Also Published As

Publication number Publication date
RU2721605C1 (en) 2020-05-21
EA202092978A3 (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MX2018015393A (en) Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof.
EA201691023A1 (en) PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
BR112019003479A2 (en) pharmaceutical formulation and composition, sealed container, subcutaneous administration device, kit, pharmaceutical unit dosage form, and method for treating an individual suffering from a masp-2 dependent complement-associated disease or disorder.
EA201892657A1 (en) SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
NO20092323L (en) Dosage and drive mechanism for drug delivery device
EA201791333A1 (en) GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
CY1111478T1 (en) Indication of Progesterone Dosage in the Treatment of Traumatic Brain Injury
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
WO2016090024A3 (en) Combination therapy for treatment of cancer
CL2018000002A1 (en) Therapeutic agent and method to treat hunter syndrome.
EA201991985A1 (en) CONJUGATES ANTIBODY-MEDICINAL PRODUCT (KALS) BASED ON GDAC INHIBITORS AND USE IN THERAPY
JP2018138596A5 (en)
MX2019014831A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor.
MX2020010119A (en) Anti-cd27 antibody, antigen-binding fragment thereof and medical use thereof.
EA202090242A1 (en) TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS
JP2017524721A5 (en)
EA202092978A2 (en) PHARMACEUTICAL COMPOSITION FOR PARENTERAL DROP INJECTION
EA201591603A1 (en) NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES
MX2021004120A (en) Dosage regimen for tfpi antagonists.
BR112017004590A2 (en) Methods for treating autoimmune disease with the use of a cd40l-targeted domain antibody
MX2023012465A (en) Anti-ifnar1 dosing regime for subcutaneous injection.
MX2021013248A (en) Dosage regimens for and compositions including anti-rsv antibodies.
EA202190294A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EA202191014A1 (en) 4-PYRAZINE-2-ILMETHYL-MORPHOLINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT